Nivolumab, a common PD-1 immune checkpoint inhibitor, exerts its antitumor effect by binding to PD-L1 on tumor cells, thereby blocking the PD-1-mediated tyrosine phosphorylation signal that inhibits T-cell activation (27). This evidence concerns the gene CD274 and neoplasm.